English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The association of  HTRA1  rs11200638 and  ARMS2  rs10490924 gene polymorphisms with response to intravitreal ranibizumab therapy among neovascular AMD (nAMD) subjects in Malaysia was determined in this study, followed by the expression of  HTRA1  and  ARMS2  genes.    Results  Both single nucleotide polymorphisms (SNPs) recorded a significant association between nAMD and controls with  HTRA1  rs11200638 at  P  = 0.018 (OR = 1.52, 95% CI = 1.07–215) and  ARMS2  rs10490924 at  P  < 0.001 (OR = 2.44, 95% CI = 1.75–3.42). An association was also observed in response to ranibizumab for both SNPs in a logistic regression analysis ( P  < 0.001). The mRNA levels in the  HTRA1  variant between responder and non-responder groups were significantly different for the homozygous non-risk GG genotype ( P  = 0.032).    Conclusions  The  HTRA1  rs11200638 and  ARMS2  rs10490924 gene polymorphisms are associated with nAMD among Malaysians. Both gene polymorphisms were also correlated with response to intravitreal ranibizumab therapy based on visual and anatomical outcomes especially the  HTRA1  rs11200638 variant.

human genomics

Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects